Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering.
Journal: BMJ open diabetes research & care
Published: December 15, 2022
Liver function markers predict cardiovascular and renal outcomes in the CANVAS Program.
Journal: Cardiovascular diabetology
Published: March 30, 2022
Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS).
Journal: Diabetes care
Published: November 17, 2021
Clinical Utility of KidneyIntelX in Early Stages of Diabetic Kidney Disease in the CANVAS Trial.
Journal: American journal of nephrology
Published: August 13, 2021
Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin.
Journal: Journal of the American College of Cardiology
Published: April 16, 2021
Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment.
Journal: Annals of internal medicine
Published: March 15, 2021
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial.
Journal: Diabetes, obesity & metabolism
Published: February 11, 2021
Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial.
Journal: Cardiovascular research
Published: September 15, 2020
Insulin-Like Growth Factor Binding Protein 7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study.
Journal: Diabetes care
Published: July 28, 2020
Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial.
Journal: The lancet. Diabetes & endocrinology
Published: June 23, 2020
Last Updated: 09/26/2026